(2S,3S)-Nemonapride (BioDeep_00000181606)

   

human metabolite blood metabolite


代谢物信息卡片


5-Chloro-2-methoxy-4-(methylamino)-N-(2-methyl-1-(phenylmethyl)-3-pyrrolidinyl)benzamide

化学式: C21H26ClN3O2 (387.17134460000005)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1C(CCN1CC2=CC=CC=C2)NC(=O)C3=CC(=C(C=C3OC)NC)Cl
InChI: InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)

描述信息

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants

同义名列表

7 个代谢物同义名

5-Chloro-2-methoxy-4-(methylamino)-N-(2-methyl-1-(phenylmethyl)-3-pyrrolidinyl)benzamide; cis-N-(1-Benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide; N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide; Nemonapride, (cis)-isomer; (2S,3S)-Nemonapride; nemonapride; Emonapride



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Pradeep Paudel, Su Hui Seong, Hyun Ah Jung, Jae Sue Choi. Characterizing fucoxanthin as a selective dopamine D3/D4 receptor agonist: Relevance to Parkinson's disease. Chemico-biological interactions. 2019 Sep; 310(?):108757. doi: 10.1016/j.cbi.2019.108757. [PMID: 31323226]
  • Daniela Noaín, M Inés Pérez-Millán, Estefanía P Bello, Guillermina M Luque, Rodrigo Casas Cordero, Diego M Gelman, Marcela Peper, Isabel García Tornadu, Malcolm J Low, Damasia Becú-Villalobos, Marcelo Rubinstein. Central dopamine D2 receptors regulate growth-hormone-dependent body growth and pheromone signaling to conspecific males. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2013 Mar; 33(13):5834-42. doi: 10.1523/jneurosci.5673-12.2013. [PMID: 23536095]
  • Marie-Bernadette Assié, Laurent Bardin, Agnès Auclair, Nathalie Consul-Denjean, François Sautel, Ronan Depoortère, Adrian Newman-Tancredi. F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice. Naunyn-Schmiedeberg's archives of pharmacology. 2007 Jun; 375(4):241-50. doi: 10.1007/s00210-007-0162-x. [PMID: 17453175]
  • P N Eswar Shankar, Anu Joseph, C S Paulose. Decreased [3H] YM-09151-2 binding to dopamine D2 receptors in the hypothalamus, brainstem and pancreatic islets of streptozotocin-induced diabetic rats. European journal of pharmacology. 2007 Feb; 557(2-3):99-105. doi: 10.1016/j.ejphar.2006.11.018. [PMID: 17174299]
  • Eun-Sook Y Lee, Hongtao Chen, Kennie R Shepherd, Nazarius S Lamango, Karam F A Soliman, Clivel G Charlton. The inhibitory role of methylation on the binding characteristics of dopamine receptors and transporter. Neuroscience research. 2004 Mar; 48(3):335-44. doi: 10.1016/j.neures.2003.11.010. [PMID: 15154679]
  • Woo-Kyu Park, Daeyoung Jeong, Cheol-Won Yun, Sunghou Lee, Heeyeong Cho, Gun-Do Kim, Hun Yeong Koh, Ae Nim Pae, Yong Seo Cho, Kyung Il Choi, Ji Young Jung, Sun Ho Jung, Jae Yang Kong. Pharmacological actions of a novel and selective dopamine D3 receptor antagonist, KCH-1110. Pharmacological research. 2003 Dec; 48(6):615-22. doi: 10.1016/s1043-6618(03)00242-1. [PMID: 14527827]
  • Atsushi Ueda, Ryoji Ozono, Tetsuya Oshima, Ai Yano, Masayuki Kambe, Yasuhiro Teranishi, Motoya Katsuki, Kazuaki Chayama. Disruption of the type 2 dopamine receptor gene causes a sodium-dependent increase in blood pressure in mice. American journal of hypertension. 2003 Oct; 16(10):853-8. doi: 10.1016/s0895-7061(03)01013-6. [PMID: 14553965]
  • Tsuyoshi Kondo, Masayuki Ishida, Noboru Tokinaga, Kazuo Mihara, Norio Yasui-Furukori, Shingo Ono, Sunao Kaneko. Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin. Progress in neuro-psychopharmacology & biological psychiatry. 2002 Feb; 26(2):287-91. doi: 10.1016/s0278-5846(01)00267-6. [PMID: 11817505]
  • K Mihara, A Suzuki, T Kondo, N Yasui-Furukori, S Ono, K Otani, S Kaneko, Y Inoue. Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. American journal of medical genetics. 2001 Apr; 105(3):271-4. doi: 10.1002/ajmg.1303. [PMID: 11353448]
  • T Kondo, K Mihara, N Yasui, U Nagashima, S Ono, S Kaneko, T Ohkubo, T Osanai, K Sugawara, K Otani. Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin. Journal of clinical psychopharmacology. 2000 Aug; 20(4):404-9. doi: 10.1097/00004714-200008000-00003. [PMID: 10917400]
  • K Mihara, T Kondo, A Suzuki, N Yasui, U Nagashima, S Ono, K Otani, S Kaneko. Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene. Psychopharmacology. 2000 Apr; 149(3):246-50. doi: 10.1007/s002139900364. [PMID: 10823405]
  • A M González, J Berciano, J Figols, A Pazos, J Pascual. Loss of dopamine uptake sites and dopamine D2 receptors in striatonigral degeneration. Brain research. 2000 Jan; 852(1):228-32. doi: 10.1016/s0006-8993(99)02205-2. [PMID: 10661519]
  • T Kondo, K Otani, N Tokinaga, M Ishida, N Yasui, S Kaneko. Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist. Journal of clinical psychopharmacology. 1999 Feb; 19(1):45-50. doi: 10.1097/00004714-199902000-00009. [PMID: 9934942]
  • T Nagasaki, T Ohkubo, K Sugawar, N Yasui, K Ohtani, S Kaneko. High-performance liquid chromatographic determination of nemonapride and desmethylnemonapride in human plasma using an electrochemical detection. Journal of chromatography. B, Biomedical sciences and applications. 1998 Sep; 714(2):293-8. doi: 10.1016/s0378-4347(98)00212-6. [PMID: 9766869]
  • H Sanada, L Yao, P A Jose, R M Carey, R A Felder. Dopamine D3 receptors in rat juxtaglomerular cells. Clinical and experimental hypertension (New York, N.Y. : 1993). 1997 Jan; 19(1-2):93-105. doi: 10.3109/10641969709080807. [PMID: 9028638]
  • G Flores, G K Wood, J J Liang, R Quirion, L K Srivastava. Enhanced amphetamine sensitivity and increased expression of dopamine D2 receptors in postpubertal rats after neonatal excitotoxic lesions of the medial prefrontal cortex. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1996 Nov; 16(22):7366-75. doi: . [PMID: 8929443]
  • K Ishiwata, K Yanai, R Iwata, T Takahashi, J Hatazawa, M Itoh, K Watabe, T Watanabe, T Ido. Analysis of plasma metabolites during human PET-studies with three receptor ligands, [11C]YM-09151-2, [11C]doxepin and [11C]pyrilamine. The Tohoku journal of experimental medicine. 1996 Feb; 178(2):129-36. doi: 10.1620/tjem.178.129. [PMID: 8727694]
  • S Kariya, S Isozaki, Y Masubuchi, T Suzuki, S Narimatsu. Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine. Biochemical pharmacology. 1995 Nov; 50(10):1645-50. doi: 10.1016/0006-2952(95)02057-8. [PMID: 7503767]
  • B P McGrath, Z Q Wang, K Shimizu, D Way, J Secombe. Suppression of noradrenaline spillover by the dopamine prodrug gamma-L-glutamyl-L-dopa: a central effect?. Hypertension research : official journal of the Japanese Society of Hypertension. 1995 Jun; 18 Suppl 1(?):S113-8. doi: 10.1291/hypres.18.supplementi_s113. [PMID: 8529039]
  • Z Q Wang, K Shimizu, D Way, J Secombe, B P McGrath. Sympatho-inhibitory effects of gamma-l-glutamyl-l-dopa are not mediated by activation of dopamine-2 receptors in conscious rabbits. Zhongguo yao li xue bao = Acta pharmacologica Sinica. 1995 May; 16(3):193-7. doi: NULL. [PMID: 7660808]
  • J A Javitch, X Li, J Kaback, A Karlin. A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice. Proceedings of the National Academy of Sciences of the United States of America. 1994 Oct; 91(22):10355-9. doi: 10.1073/pnas.91.22.10355. [PMID: 7937955]
  • J W Boja, M A Rahman, A Philip, A H Lewin, F I Carroll, M J Kuhar. Isothiocyanate derivatives of cocaine: irreversible inhibition of ligand binding at the dopamine transporter. Molecular pharmacology. 1991 Mar; 39(3):339-45. doi: NULL. [PMID: 1826041]
  • H M Siragy, R A Felder, N L Howell, R L Chevalier, M J Peach, R M Carey. Evidence that dopamine-2 mechanisms control renal function. The American journal of physiology. 1990 Nov; 259(5 Pt 2):F793-800. doi: 10.1152/ajprenal.1990.259.5.f793. [PMID: 1978572]
  • R A Felder, M G Seikaly, P Cody, G M Eisner, P A Jose. Attenuated renal response to dopaminergic drugs in spontaneously hypertensive rats. Hypertension (Dallas, Tex. : 1979). 1990 Jun; 15(6 Pt 1):560-9. doi: 10.1161/01.hyp.15.6.560. [PMID: 1971811]
  • M Domae, K Yamada, Y Hanabusa, S Matsumoto, T Furukawa. Decrease of prolactin secretion via stimulation of pituitary dopamine D-2 receptors after application of talipexole and SND 919. European journal of pharmacology. 1990 Apr; 179(1-2):75-82. doi: 10.1016/0014-2999(90)90403-s. [PMID: 2142088]
  • K Hatano, K Ishiwata, K Kawashima, J Hatazawa, M Itoh, T Ido. D2-dopamine receptor specific brain uptake of carbon-11-labeled YM-09151-2. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1989 Apr; 30(4):515-22. doi: . [PMID: 2567779]
  • S Higuchi, K Yokoi, Y Soeishi, S Kawamura. Comparative pharmacokinetics of a new benzamide neuroleptic drug in rats, dogs and monkeys using a stable isotope technique. Xenobiotica; the fate of foreign compounds in biological systems. 1986 Jan; 16(1):79-86. doi: 10.3109/00498258609043508. [PMID: 2868578]
  • H Kaji, K Chihara, N Minamitani, H Kodama, T Kita, T Fujita. Effect of various catecholamine antagonists on prolactin secretion in conscious male rabbits. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). 1985 Oct; 180(1):144-8. doi: 10.3181/00379727-180-42156. [PMID: 2863827]
  • H Y Meltzer, M Mikuni, M Simonovic, G A Gudelsky. Effect of a novel benzamide, YM-09151-2, on rat serum prolactin levels. Life sciences. 1983 Feb; 32(9):1015-21. doi: 10.1016/0024-3205(83)90933-5. [PMID: 6827920]